Skip to content
Open in App
Hansoh Pharmaceutical Group logo

Hansoh Pharmaceutical Group

web2

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the rese...

Symbol · 3692
Company profile

About

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

ARTEMIS 011 Phase III study of HS 20093 met its primary endpoint

KEY STEP

Hansoh announced that the ARTEMIS 011 Phase III trial of risvutatug rezetecan in previously treated osteosarcoma met its primary endpoint of independent review committee assessed progression free survival. The company also reported consistent benefit across secondary endpoints and no new safety signals.

Roadmap reference

Hansoh licensed overseas rights to HS 20118 to Avere Therapeutics

KEY STEP

Hansoh announced an exclusive licensing agreement granting Avere Therapeutics rights to develop, manufacture and commercialize HS 20118 outside mainland China, Hong Kong, Macau and Taiwan. Hansoh is eligible for US$120 million in upfront payments, up to US$2.18 billion in milestones and royalties on future sales.

Roadmap reference

China accepted the HS 20093 biologics license application for small cell lung cancer

KEY STEP

Hansoh announced that the National Medical Products Administration accepted the biologics license application for HS 20093 for adults with small cell lung cancer after failure of prior platinum based chemotherapy. The application is supported by the ARTEMIS 008 Phase III study.

Roadmap reference
People

Company team

HZ

Huijuan Zhong

Founder, Chairlady & CEO

Company leadership profile.

AL

Aifeng Lyu

Executive Director

Company leadership profile.

YS

Yuan Sun

Executive Director

Company leadership profile.

SW

Sheung Wai Chan

Independent Non-Executive Director

Company leadership profile.

DY

Dongtao Yang

Independent Non-Executive Director

Company leadership profile.

GL

Guoqiang Lin

Independent Non-Executive Director

Company leadership profile.

JY

Jia Yan

Independent Non-Executive Director

Company leadership profile.

Expert coverage

1 expert evaluated Hansoh Pharmaceutical Group.

Orbitrum research

Experts evaluating Hansoh Pharmaceutical Group

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment